These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16922652)

  • 1. In vitro screening of drug metabolism during drug development: can we trust the predictions?
    Pelkonen O; Raunio H
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):49-59. PubMed ID: 16922652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
    Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
    Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery.
    Prakash C; Sharma R; Gleave M; Nedderman A
    Curr Drug Metab; 2008 Nov; 9(9):952-64. PubMed ID: 18991592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of drug metabolism and interactions on the basis of in vitro investigations.
    Pelkonen O; Turpeinen M; Uusitalo J; Rautio A; Raunio H
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):167-75. PubMed ID: 15733211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.
    Bhushan A; Martucci NJ; Usta OB; Yarmush ML
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):475-7. PubMed ID: 26940609
    [No Abstract]   [Full Text] [Related]  

  • 8. The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development.
    Ball SE; Scatina JA; Sisenwine SF; Fisher GL
    Drug Chem Toxicol; 1995 Feb; 18(1):1-28. PubMed ID: 7768197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in silico prediction of human-specific metabolites from hepatotoxic drugs.
    Valerio LG; Long A
    Curr Drug Discov Technol; 2010 Sep; 7(3):170-87. PubMed ID: 20843294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE; Lopez-Anaya A
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application and development of in vitro metabolism study at early drug discovery stage].
    Wu H; Peng Y; Sun JG; Zhang XY; Zhong YX; Wang GJ
    Yao Xue Xue Bao; 2013 Jul; 48(7):1071-9. PubMed ID: 24133972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models.
    Hop CE; Cole MJ; Davidson RE; Duignan DB; Federico J; Janiszewski JS; Jenkins K; Krueger S; Lebowitz R; Liston TE; Mitchell W; Snyder M; Steyn SJ; Soglia JR; Taylor C; Troutman MD; Umland J; West M; Whalen KM; Zelesky V; Zhao SX
    Curr Drug Metab; 2008 Nov; 9(9):847-53. PubMed ID: 18991580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
    Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
    Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of drug metabolites.
    Izumi T
    Drug Metab Pharmacokinet; 2011; 26(2):121-2. PubMed ID: 21532211
    [No Abstract]   [Full Text] [Related]  

  • 16. Can drug-drug interactions be predicted from in vitro studies?
    Kremers P
    ScientificWorldJournal; 2002 Mar; 2():751-66. PubMed ID: 12806001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
    Dalvie D; Obach RS; Kang P; Prakash C; Loi CM; Hurst S; Nedderman A; Goulet L; Smith E; Bu HZ; Smith DA
    Chem Res Toxicol; 2009 Feb; 22(2):357-68. PubMed ID: 19146377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of in vitro preparations for semi-quantitative prediction of in vivo drug metabolism.
    De Graaf IA; Van Meijeren CE; Pektaş F; Koster HJ
    Drug Metab Dispos; 2002 Oct; 30(10):1129-36. PubMed ID: 12228190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.
    Uetrecht J
    Drug Discov Today; 2003 Sep; 8(18):832-7. PubMed ID: 12963319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.